Which drug should not be used to treat severe bradycardia caused by excessive beta-adrenergic blockade?

Which drug should not be used to treat severe bradycardia caused by excessive beta-adrenergic blockade?

• A. Atropine
• B. Dobutamine
• C. Dopamine
• D. Glucagon

Answer: (C)

When beta-blockade is causing severe bradycardia, the heart’s response to catecholamines is blunted because the beta-adrenergic receptors are blocked. The most effective way to counteract this is to bypass the blocked receptors and increase cardiac activity through a non–beta-adrenergic mechanism. Glucagon fits this approach by raising intracellular cAMP in cardiac cells via its own receptor, improving heart rate and contractility independently of beta receptors. Dopamine, on the other hand, largely acts through beta-1 receptors (especially at intermediate doses) to increase heart rate and contractility. If those receptors are blocked, dopamine’s chronotropic and inotropic effects are diminished, making it unlikely to correct the bradycardia. It can also raise blood pressure through alpha effects at higher doses, which may complicate the hemodynamic picture. That’s why dopamine is not the preferred choice in this scenario. In this context, atropine can be tried for bradycardia, but glucagon is the more reliable option because it does not depend on beta-adrenergic signaling to exert its beneficial effects.

When beta-blockade is causing severe bradycardia, the heart’s response to catecholamines is blunted because the beta-adrenergic receptors are blocked. The most effective way to counteract this is to bypass the blocked receptors and increase cardiac activity through a non–beta-adrenergic mechanism. Glucagon fits this approach by raising intracellular cAMP in cardiac cells via its own receptor, improving heart rate and contractility independently of beta receptors.

Dopamine, on the other hand, largely acts through beta-1 receptors (especially at intermediate doses) to increase heart rate and contractility. If those receptors are blocked, dopamine’s chronotropic and inotropic effects are diminished, making it unlikely to correct the bradycardia. It can also raise blood pressure through alpha effects at higher doses, which may complicate the hemodynamic picture. That’s why dopamine is not the preferred choice in this scenario.

In this context, atropine can be tried for bradycardia, but glucagon is the more reliable option because it does not depend on beta-adrenergic signaling to exert its beneficial effects.